The Bad Reputation of Digoxin in Atrial Fibrillation-Causality or Bias? Nationwide Nested Case-Control Study.

ABSTRACT:

Aims

Studies have reported excess risk of mortality associated with digoxin in atrial fibrillation (AF).This study sought to investigate if these findings could be replicated and whether a potential association could be explained by bias.

Methods

Using Danish Nationwide registers, a nested-case control study from 2012 to 2022 was conducted in a cohort of patients with AF. Cases were defined as death of any cause and the exposure was treatment with digoxin compared with beta blockers/verapamil. To investigate bias, additional analyses with negative control outcomes as case definitions-in which we would not expect a plausible association (eg, nursing home admission)-were employed. Associations were reported as hazard ratios (HRs) with 95% confidence intervals (95% CI).

Resu

SUBMITTER: Holt A 

PROVIDER: S-EPMC11957803 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature